OS Therapies, Inc., a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced that it received a Notice of Allowance from the United ...

Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...

PITTSBURGH, PA, USA I February 20, 2025 I Myris Therapeutics™ emerged from stealth today to announce its strategic focus. Myris, formerly known as ...

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus ...